CICP17: A promising drug target and biomarker for cancer treatment

Target Name: CICP17

NCBI ID: G642663

CICP17

Other Name(s): capicua transcriptional repressor pseudogene 17 | Capicua transcriptional repressor pseudogene 17

CICP17: A promising drug target and biomarker for cancer treatment

Introduction

Cancer is a leading cause of human mortality worldwide, with over 20% of the global population affected. The development of new treatments is crucial for improving survival rates and quality of life. CICP17, or capicua transcriptional repressor pseudogene 17, is a gene that has been identified as a potential drug target and biomarker for cancer. In this article, we will explore the research on CICP17 and its potential as a drug target and biomarker.

CICP17 gene and function

CICP17 is a gene located on chromosome 6p21.2, which encodes a protein known as CRTBP. CRTBP is a transcription factor, which plays a crucial role in the regulation of gene expression. Studies have shown that CRTBP binds to DNA-specific binding sites. Control gene expression. Variations in the CICP17 gene are closely related to the risk of various cancers, such as lung cancer, liver cancer, breast cancer, etc.

Possibility of CICP17 as a drug target

Variations in CICP17 are closely related to the risk of cancer, so CICP17 is regarded as a potential drug target. Drug targets refer to biological molecules that can interfere with key molecules in the growth, division, and survival of tumor cells. Studies have shown that CICP17 is closely related to the risk of various cancers, such as lung cancer, liver cancer, breast cancer, etc. In addition, CICP17 gene expression levels are closely related to the prognosis of various cancers, such as the survival rate of lung cancer patients. Therefore, CICP17 is regarded as a potential drug target.

CICP17 as a tumor biomarker

CICP17 gene expression level is closely related to tumor progression and invasion. Studies have shown that high CICP17 expression levels are positively correlated with tumor progression and invasion. In addition, CICP17 gene expression level is also closely related to the prognosis of tumors, such as the survival rate of lung cancer patients. Therefore, CICP17 can be used as a tumor biomarker to evaluate the prognosis and treatment effect of tumor patients.

Therapeutic prospects of CICP17

CICP17 gene expression level is closely related to tumor progression and invasion. Therefore, CICP17 is regarded as a potential drug target. Currently, researchers are exploring the use of anti-CICP17 drugs to treat a variety of cancers. For example, there have been some studies exploring the use of anti-CICP17 drugs to treat lung, liver, and breast cancer. These findings indicate that CICP17 anti-drugs can significantly inhibit tumor growth and progression and improve patient survival rates.

in conclusion

CICP17 is a potential drug target that can be used to treat various cancers. By inhibiting CICP17 gene expression, the growth and division of tumor cells can be controlled. Currently, there are already some anti-CICP17 drugs in clinical research, which can significantly inhibit tumor growth and progression and improve patient survival rates. Therefore, CICP17 is a potential drug target worthy of further study.

Protein Name: Capicua Transcriptional Repressor Pseudogene 17

The "CICP17 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CICP17 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets